Get started
Author

Valerie L. Pivorunas

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
2022 · Geert D'Haens, Remo Panaccione, et al. · The Lancet · 466
PDF
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
2022 · Marc Ferrante, Remo Panaccione, et al. · The Lancet · 382
PDF
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
2024 · Laurent Peyrin-Biroulet, J. Casey Chapman, et al. · New England Journal of Medicine · 225
Risankizumab for Ulcerative Colitis
2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 166
Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair
2021 · Lori Patnaude, Martha Mayo, et al. · Life Sciences · 124
PDF
Risankizumab: Mechanism of action, clinical and translational science
2024 · Yinuo Pang, Ronilda D'Cunha, et al. · Clinical and Translational Science · 55
PDF
A population of proinflammatory T cells coexpresses αβ and γδ T cell receptors in mice and humans
2020 · Sarah C. Edwards, Caroline E. Sutton, et al. · The Journal of Experimental Medicine · 46
The Transmembrane Segment of a Tail-anchored Protein Determines Its Degradative Fate through Dislocation from the Endoplasmic Reticulum
2010 · Jasper H.L. Claessen, Britta Mueller, et al. · Journal of Biological Chemistry · 36
PDF
SpoIIIE Protein Achieves Directional DNA Translocation through Allosteric Regulation of ATPase Activity by an Accessory Domain
2013 · Marina Besprozvannaya, Valerie L. Pivorunas, et al. · Journal of Biological Chemistry · 30
Common Diseases in Clinical Cohorts — Not Always What They Seem
2025 · Fedik Rahimov, Benjamin M. Jacobs, et al. · New England Journal of Medicine · 21
Whole Blood DNA Methylation Changes Are Associated with Anti-TNF Drug Concentration in Patients with Crohn’s Disease
2023 · Simeng Lin, Eilis Hannon, et al. · Journal of Crohn s and Colitis · 19
PDF
Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
2012 · Maria A Argiriadi, Eric R Goedken, et al. · BMC Structural Biology · 17
PDF
S1 Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial
2023 · Laurent Peyrin-Biroulet, Casey Chapman, et al. · The American Journal of Gastroenterology · 13
HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn’s Disease Studies
2024 · Mark Reppell, Xiuwen Zheng, et al. · Journal of Crohn s and Colitis · 12
Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn’s Disease in the SERENE Studies
2023 · Bram Verstockt, Valerie Pivorunas, et al. · Journal of Crohn s and Colitis · 12
PDF
Mechanistic Study of Classical Translocation-Dead SpoIIIE36 Reveals the Functional Importance of the Hinge within the SpoIIIE Motor
2014 · Marina Besprozvannaya, Valerie L. Pivorunas, et al. · Journal of Bacteriology · 8
PDF
Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients
2023 · Benjamin Y H Bai, Mark Reppell, et al. · Journal of Crohn s and Colitis · 7
PDF
DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studies
2022 · B Verstockt, N Al Mahi, et al. · Journal of Crohn s and Colitis · 4
PDF
DOP88 Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn’s disease
2023 · S Lin, E Hannon, et al. · Journal of Crohn s and Colitis · 3
PDF
158 – Leveraging Human Intestinal Organoids to Advance Il-22-Based Therapies for Ulcerative Colitis
2019 · Lori Patnaude, Martha Mayo, et al. · Gastroenterology · 2
O23 Risankizumab vs ustekinumab for patients with moderate-to-severe crohn’s disease: results from the phase 3b SEQUENCE study
2024 · James Lindsay, Laurent Peyrin-Biroulet, et al. · Gut · 1
P067 Advancing IL-22-Based Therapies for Inflammatory Bowel Diseases With Human Intestinal Organoids
2019 · Lori Patnaude, Martha Mayo, et al. · The American Journal of Gastroenterology · 1
Su1739 RISANKIZUMAB, BUT NOT USTEKINUMAB OR VEDOLIZUMAB, DOWNREGULATES IL-23-INDUCED MUCOSAL PATHOGENIC TH17 CELLS IN PATIENTS WITH CROHN'S DISEASE
2024 · Daniele Noviello, Irene Dusetti, et al. · Gastroenterology
P981 Risankizumab, but not ustekinumab or vedolizumab, downregulates IL-23-induced mucosal pathogenic Th17 cells in patients with Crohn’s disease
2024 · D Noviello, I Dusetti, et al. · Journal of Crohn s and Colitis
PDF
P746 Identification of Altered Microbial Genera at Baseline in Adalimumab Clinical Remitters and an Absence of Change in Total Microbial Composition Post Induction Treatment in the SERENE UC Study
2023 · Y Morsy, V Pivorunas, et al. · Journal of Crohn s and Colitis
PDF
Works count: 31
Citation count: 1,650
H-index: 13
I10-index: 15
Year
Topic
Type